Login / Signup

Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs.

Alessandra IurloDaniele CattaneoAlessandra MalatoVincenzo AccursoMario AnnunziataAntonella GozziniAnna Rita ScortechiniCristina BucelliEmilia ScalzulliImma AttolicoAlessandro MaggiBruno MartinoGiovanni CaocciElisabetta AbruzzesePatrizia PregnoLuigiana LucianoMassimo Breccia
Published in: American journal of hematology (2020)
Keyphrases
  • chronic myeloid leukemia
  • low dose
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • high dose
  • patient reported outcomes